Evotec SE (EVOTF)
Company Description
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.
It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals.
The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019.
Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
| Country | DE |
| IPO Date | Oct 7, 2009 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4,740 |
| CEO | Dr. Christian Wojczewski Ph.D. |
Contact Details
Address: Essener Bogen 7 Hamburg, DE | |
| Website | https://www.evotec.com |
Stock Details
| Ticker Symbol | EVOTF |
| Exchange | PNK |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001412558 |
| CUSIP Number | n/a |
| ISIN Number | DE0005664809 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christian Wojczewski Ph.D. | Chief Executive Officer & Management Board Member |
| Aurelie Dalbiez | Chief People Officer & Member of Management Board |
| Paul Hitchin | Chief Financial Officer |
| Christiane Honisch | SVice President Head of Diagnostics |
| Dr. Christian Dargel | EVice President Global Head of Legal & Compliance |
| Dr. Cord Dohrmann Ph.D. | Chief Scientific Officer & Member of Management Board |
| Dr. David Hallet | Executive Vice President |
| Dr. Ian M. Hunneyball | Senior Vice President of Programme Management & Clinical Operations |
| Uwe Andag | EVice President Head of Metabolic Diseases |
| Volker Braun | Executive Vice President and Head of Global Investor Relations & ESG |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | 20-F | Filing |
| Apr 17, 2025 | 6-K | Filing |
| Apr 17, 2025 | 6-K | Filing |
| Nov 29, 2024 | 6-K | Filing |
| Nov 22, 2024 | 6-K | Filing |
| Nov 15, 2024 | 6-K | Filing |
| Nov 08, 2024 | SC 13D | Filing |
| Nov 06, 2024 | 6-K | Filing |
| Aug 14, 2024 | 6-K | Filing |
| Aug 14, 2024 | 20-F | Filing |